josh hardman

After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data - Psychedelic Alpha Researchers, clinicians and executives react to Compass Pathways’ second positive Phase 3 psilocybin readout in treatment-resistant depression.

After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data

Researchers, clinicians and executives react to Compass Pathways’ second positive Phase 3 psilocybin readout in treatment-resistant depression.

psychedelicalpha.com/news/after-t...

Citizen Request for Congressional Oversight Psychedelic Research, Advocacy, and Commercialization Ecosystem

The author is encouraging people to contact their Reps.

I won't share the 'Entities in Scope' here (seems to be cribbed from Psymposia's 'The Syndicate'), but you can find them here: tinawill.substack.com/p/citizen-re...

Someone has written a 'Request for Congressional Oversight' of certain psychedelics orgs

Psymposia and Psychedelic Alpha = only sources cited. PSA: Psychedelic Alpha is not involved.

In fact, the author harassed me last spring and threatened to contact Interpol(!)

Bizarre.

⚖️🇺🇲 January 2026 Psychedelic Bill Round-Up: 75 Bills in Flight... and Counting

Legislative sessions across the U.S. have got off to a lively start this year, with dozens of new psychedelics-related bills introduced.

psychedelicalpha.com/news/january...

Psychedelic Bill Tracker - Psychedelic Alpha A Pα+ tool that allows you to monitor the status of psychedelics-related bills working their way through both state and federal legislatures in the U.S.

Introducing the Pα+ Psychedelic Bill Tracker

Monitor the status of every psychedelics-related bill working its way through both state and federal legislatures in the U.S.

Available now: psychedelicalpha.com/data/psyched...

With psychedelic mental health therapies on the horizon, Americans are open to learning more Ipsos research examines information pathways and attitudes regarding the use of psychedelics in mental health treatment

New: Ipsos/Psychedelic Alpha polling on how Americans view psychedelics.

"With psychedelic mental health therapies on the horizon, Americans are open to learning more"

www.ipsos.com/en-us/psyche...

Pα+ Psychedelic Bulletin #217: Gilgamesh’s GM-1020 Prints Positive Topline; FDA Lifts Hold on GH Research’s 5-MeO-DMT IND; Compass Details Pivotal PTSD Trial Design; Cybin Becomes Helus - Psychedelic ... Gilgamesh Prints Positive Topline from Phase 2a Study of NMDA Receptor Agonist for MDD • FDA Lifts Hold on GH Research’s Inhaled 5-MeO-DMT IND After More than Two Years • Cybin Rebrands to Helus…

Pα+ Psychedelic Bulletin #217:

- Gilgamesh’s GM-1020 Prints Positive Topline

- FDA Lifts Hold on GH Research’s 5-MeO-DMT IND

- Compass Details Pivotal PTSD Trial Design

- Cybin Becomes Helus

- much more...

psychedelicalpha.com/news/p%ce%b1...

2025 Year in Review: Future(s) & Open Questions (Video) - Psychedelic Alpha In the third video of a three-part series, Psychedelic Alpha’s Josh Hardman takes a look at some broader open questions and potential futures in the psychedelics field via a narrated presentation.

🎥 2025 Year in Review: Future(s) & Open Questions

Watch the third and final video in our 2025 Year in Review series.

psychedelicalpha.com/news/2025-ye...

Year in Review: Psychedelics in 2025 (Video) - Psychedelic Alpha In the first of a three-part series, Psychedelic Alpha’s Josh Hardman takes a look back at 2025 via a narrated presentation. In this hour-long video, Hardman reviews developments across psychedelic…

🎥 Out now: Part 1 of our 3-part 2025 Year in Review video Series

In this session, I take stock of where the psychedelics field stands today across drug development, policy, and access programmes in this hour-long video, which focuses on 2025.

psychedelicalpha.com/news/year-in...

Pα+ Psychedelic Bulletin #216: Australia’s Psychedelics-for-Veterans Funding; New Mexico Targets 2026 Medical Psilocybin Launch; Radial Scores $50M; Otsuka’s “Novel Serotonergic Agonists”; Psilocybin ... Australia’s Department of Veterans’ Affairs Explains World-First Funding Model for Psychedelic-Assisted Psychotherapy • New Mexico Targets December 2026 for Medical Psilocybin Launch •

Pα+ Psychedelic Bulletin #216:

- Australia’s Psychedelics-for-Veterans Funding

- New Mexico Targets 2026 Medical Psilocybin Launch

- Otsuka’s “Novel Serotonergic Agonists”

- Psilocybin Accelerates Brain Tumour Growth in Mice

- TX $50M Ibogaine Study

psychedelicalpha.com/news/p%ce%b1...

Serotonergic neuron-glioma interactions drive high-grade glioma pathophysiology High-grade gliomas are lethal brain cancers that are powerfully regulated by glutamatergic neurons through activity-dependent paracrine factors and functional neuron-to-glioma synapses. Here, we repor...

Preprint: www.biorxiv.org/content/10.6...

🐁 Very concerning finding: Psilocybin promotes brain tumour growth

Authors caution against use of 5-HT2A agonists like psilocybin in patients with glioma, "given the profound and sustained tumor growth-promoting effects observed."

Extends to other serotonergic drugs like LSD.

The Psychedelic Practitioner Issue 2: Preparation

We explore the science and practice of psychedelic preparation through interviews, research reviews, and practitioner insights.

Read now: psychedelicalpha.com/news/the-psy...

The View from D.C.: Psychedelic Politics, Blockers and Approvals on the Horizon - Psychedelic Alpha Psychedelic Alpha’s Josh Hardman reports from Washington, D.C., where conversations with regulators, lawmakers, and insiders suggest a turbulent but potentially transformative period ahead.

The View from D.C.: Psychedelic Politics, Blockers and Approvals on the Horizon

I report from Washington, D.C., where conversations with regulators, lawmakers, and insiders suggest a turbulent but potentially transformative period ahead.

psychedelicalpha.com/news/the-vie...

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and Competition - Psychedelic Alpha Psychedelic Alpha’s Josh Hardman sits down with Compass Pathways’ Chief Patient Officer, Steve Levine, at a pivotal time for the company. In this wide-ranging discussion, the pair cover these…

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and Competition

I spoke with the Compass exec at a pivotal time for the company, covering clinical infrastructure and credentialing through to comps and competition.

psychedelicalpha.com/news/bringin...

ARPA-H Launches $100M Effort to “Demystify” Mental Health and Catalyse Rapid-Acting Behavioural Health Therapeutics, Including Psychedelics - Psychedelic Alpha The Advanced Research Projects Agency for Health (ARPA-H) has carved out up to $100M for an initiative that aims to develop objective measures of mental and behavioural health, it announced today.

BREAKING: ARPA-H Launches $100M Effort to “Demystify” Mental Health and Catalyse Rapid-Acting Behavioural Health Therapeutics, Including Psychedelics

The U.S government agency revealed the project this evening. Read our breaking news story...

psychedelicalpha.com/news/arpa-h-...

Thanks, Rich! @michaelhaichin.bsky.social helped with it, too.

Looking forward to the full publication.

Pα+ Psychedelic Bulletin #214: LSD Microdosing Program Collapses; AtaiBeckley’s Phase 2b Debrief; UK Government Responds to MPs’ Psilocybin-Related Questions - Psychedelic Alpha Largest LSD Microdosing Trial to Date Fails Across All Endpoints • AtaiBeckley’s Phase 2b Debrief: More Detail on SAE and Phase 3 Considerations • UK Government Holds Line on Psilocybin Despite New…

Psychedelic Bulletin 214:

- Largest LSD Microdosing Trial Fails Across All Endpoints

- AtaiBeckley’s Phase 2b Debrief

- UK Gov. Holds Line on Psilocybin Despite MPs' Written Questions

- MAHA Summit ft. Psychedelics

- VA's Ph 3 Psilocybin Study

- More...

psychedelicalpha.com/news/p%ce%b1...

Beyond the Brain Reset: Óscar Soto on Mechanisms of Psychedelic Action - Psychedelic Alpha In this interview with Psychedelic Alpha’s Josh Hardman, psychiatrist, therapist and researcher Dr. Óscar Soto discusses psychedelic trial design, therapeutic fidelity, and the evolving role of…

Beyond the Brain Reset: Óscar Soto on Mechanisms of Psychedelic Action

psychedelicalpha.com/news/beyond-...

AtaiBeckley Posts Positive Phase 2b Open-Label Extension Data for 5-MeO-DMT, Plots Phase 3 - Psychedelic Alpha This morning, AtaiBeckley shared positive topline data from the open-label portion of its Phase 2b trial of intranasal 5-MeO-DMT (BPL-003) in patients with treatment-resistant depression (TRD)…

AtaiBeckley Posts Positive Phase 2b Open-Label Extension Data for 5-MeO-DMT, Plots Phase 3

We reviewed the readout and spoke with AtaiBeckley ( $ATAI ) CEO, Srinivas Rao, to dive deeper…

psychedelicalpha.com/news/ataibec...

Pα+ Psychedelic Bulletin #213: Compass Accelerates Psilocybin Launch Planning; Australian VA Funds Psychedelic Therapy for Veterans; AbbVie Paid $900M Upfront for Psychedelic Candidate - Psychedelic A... Compass Accelerates Psilocybin Launch Plans by Almost a Year • Australia’s VA Will Fund Psychedelic-Assisted Psychotherapy for Veterans • AbbVie Paid $900M Upfront for Gilgamesh’s Psychedelic Candidat...

Psychedelic Bulletin 213

- Compass Accelerates Psilocybin Launch Plans by Almost a Year

- Australia’s VA Will Fund Psychedelic-Assisted Psychotherapy for Veterans

- AbbVie Paid $900M Upfront for Gilgamesh’s Psychedelic Candidate

psychedelicalpha.com/news/p%ce%b1...

Compass Pathways Accelerates Psilocybin Launch Timeline by 9-12 Months - Psychedelic Alpha This morning, Compass Pathways announced that it is preparing to launch its psilocybin therapy (COMP360) for treatment-resistant depression (TRD) at least nine months earlier than previously planned…

BREAKING: Compass Pathways Accelerates Psilocybin Launch Timeline by 9-12 Months

More detail, including interview with $CMPS CEO Kabir Nath, in our coverage...

psychedelicalpha.com/news/compass...

Pα+ Psychedelic Bulletin #212: Delix Posts Early Efficacy Signal; NRx Wants FDA to Ban Competitors’ Ketamine; Cybin Raises $175M - Psychedelic Alpha Delix Therapeutics Posts Early Efficacy Signal for ‘Non-Hallucinogenic’ Neuroplastogen as FDA Clears At-Home Phase II • NRx Pharmaceuticals Wants FDA to Ban Its Competitors’ Ketamine •

Pα+ Psychedelic Bulletin 212

- Delix Posts Early Efficacy Signal for ‘Non-Hallucinogenic’ Neuroplastogen as FDA Clears At-Home Phase II

- NRx Wants FDA to Ban Its Competitors’ Ketamine

- Cybin Trades Toxic Financing for Top Tier Investors in $175M Raise

psychedelicalpha.com/news/p%ce%b1...

Federal Psychedelics Lobbying Tracker - Psychedelic Alpha Charts that visualise the extent of psychedelics organisations’ lobbying activities at the federal level, at least according to filings. Updated quarterly.

You can now also explore this data via our Psychedelics Federal Lobbying Tracker.

Access here: psychedelicalpha.com/data/federal...

Q3’25 Psychedelic Lobbying Update - Psychedelic Alpha Each quarter, we provide a look at federal lobbying disclosures by psychedelic drug developers and nonprofits. Here, we share our analysis of the latest developments for our Pα+ subscribers.

Q3’25 Psychedelic Lobbying Update

Here, we share our analysis of the latest developments in federal psychedelics lobbying for our Pα+ subscribers.

Here’s a review of Q3 2025 activity…

psychedelicalpha.com/news/q325-ps...

Pα+ Psychedelic Bulletin #211: AbbVie Officially Enters Psychedelics; FDA Gives atai-Beckley’s 5-MeO-DMT Breakthrough Therapy Status; Newsom Signs Psychedelics Bill; No Priority Vouchers for Psychedel... AbbVie Officially Enters Psychedelics as Gilgamesh Deal Closes, Patent Dispute Opens • BPL-003 Wins Breakthrough Status as atai Raises $150M • FDA Passes on Psychedelics in First Round of Priority Vou...

Pα+ Psychedelic Bulletin #211:

- AbbVie Officially Enters Psychedelics

- atai-Beckley’s 5-MeO-DMT Scores Breakthrough Therapy Designation

- California Bill Signed

- No Commissioner's National Priority Voucher for Psychedelics

- and more...

psychedelicalpha.com/news/p%ce%b1...

A European Model: Robert Schoevers on the Continent’s Growing Psychedelic Research Agenda

I speak with Schoevers, psychiatrist & epidemiologist who is, among other things, PI of PsyPal, a large, EU-funded study of psilocybin in patients w/ palliative care needs

psychedelicalpha.com/news/a-europ...

Recovered or Reimagined? Samuli Kangaslampi on Psychedelics and Autobiographical Recall - Psychedelic Alpha Psychedelic Alpha’s Josh Hardman speaks with clinical psychologist and trauma researcher Dr. Samuli Kangaslampi about how psychedelics affect autobiographical memory. They discuss the historical…

Had a chat with @josh-hardman.bsky.social of @psychedelicalpha.bsky.social recently about recovered memories under #psychedelics. psychedelicalpha.com/news/recover...

The Psychedelic Practitioner: Issue 1 - Psychedelic Alpha Welcome to the inaugural issue of The Psychedelic Practitioner, a new publication for the evolving practice of psychedelic care.

Today, we launch The Psychedelic Practitioner by Psychedelic Alpha

It’s designed specifically for therapists, clinicians, facilitators, and other professionals working with—or preparing to work with—psychedelic therapies and related treatments.

Read now: psychedelicalpha.com/news/the-psy...

Q3 2025 Psychedelic Investor Survey Results

Today, we share topline results from the latest in our series of psychedelics investor surveys.

Explore: psychedelicalpha.com/news/psyched...